Search Results - "Loges, S"

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells by Hvichia, G.E., Parveen, Z., Wagner, C., Janning, M., Quidde, J., Stein, A., Müller, V., Loges, S., Neves, R.P.L., Stoecklein, N.H., Wikman, H., Riethdorf, S., Pantel, K., Gorges, T.M.

“…Circulating tumor cells (CTCs) were introduced as biomarkers more than 10 years ago, but capture of viable CTCs at high purity from peripheral blood of cancer…”
Get full text

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B by Wroblewski, M., Bauer, R., Cubas Córdova, M., Udonta, F., Ben-Batalla, I., Legler, K., Hauser, C., Egberts, J., Janning, M., Velthaus, J., Schulze, C., Pantel, K., Bokemeyer, C., Loges, S.

“…Resistance towards VEGF-centered anti-angiogenic therapy still represents a substantial clinical challenge. We report here that mast cells alter the…”
Get full text

Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates by Loges, Sonja, Schmidt, Thomas, Carmeliet, Peter

“…The concept of inhibiting tumor neovessels has taken the hurdle from the bench to the bedside and now represents an extra pillar of anticancer treatment. So…”
Get full text

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer by Lindsay, C.R., Blackhall, F.H., Carmel, A., Fernandez-Gutierrez, F., Gazzaniga, P., Groen, H.J.M., Hiltermann, T.J.N., Krebs, M.G., Loges, S., López-López, R., Muinelo-Romay, L., Pantel, K., Priest, L., Riethdorf, S., Rossi, E., Terstappen, L., Wikman, H., Soria, J.-C., Farace, F., Renehan, A., Dive, C., Besse, B., Michiels, S.

“…We assessed the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with advanced non-small cell lung cancer…”
Get full text

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development by Westphalen, C B, Martins-Branco, D, Beal, J R, Cardone, C, Coleman, N, Schram, A M, Halabi, S, Michiels, S, Yap, C, André, F, Bibeau, F, Curigliano, G, Garralda, E, Kummar, S, Kurzrock, R, Limaye, S, Loges, S, Marabelle, A, Marchió, C, Mateo, J, Rodon, J, Spanic, T, Pentheroudakis, G, Subbiah, V

“…Advances in precision oncology led to approval of tumour-agnostic molecularly guided treatment options (MGTOs). The minimum requirements for claiming…”
Get more information

RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients by Carmeliet, P, Li, X, Treps, L, Conradi, L-C, Loges, S

Get full text

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing by Christopoulos, P., Kirchner, M., Roeper, J., Saalfeld, F., Janning, M., Bozorgmehr, F., Magios, N., Kazdal, D., Volckmar, A.L., Brückner, L.M., Bochtler, T., Kriegsmann, M., Endris, V., Penzel, R., Kriegsmann, K., Eichhorn, M., Herth, F.J.F., Heussel, C.P., El Shafie, R.A., Schneider, M.A., Muley, T., Meister, M., Faehling, M., Fischer, J.R., Heukamp, L., Schirmacher, P., Bischoff, H., Wermke, M., Loges, S., Griesinger, F., Stenzinger, A., Thomas, M.

“…•EGFR variant, TP53 and brain status together predict survival in EGFR+ NSCLC (ENS).•Co-mutations beyond TP53 are rare and their clinical significance remains…”
Get full text

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition by Schiffmann, L M, Brunold, M, Liwschitz, M, Goede, V, Loges, S, Wroblewski, M, Quaas, A, Alakus, H, Stippel, D, Bruns, C J, Hallek, M, Kashkar, H, Hacker, U T, Coutelle, O

“…Background: Vascular endothelial growth factor (VEGF)-targeting drugs normalise the tumour vasculature and improve access for chemotherapy. However, excessive…”
Get full text

RAISEing VEGF-D’s importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients by Carmeliet, P., Li, X., Treps, L., Conradi, L.-C., Loges, S.

Get full text

Development of targeted angiogenic medicine by LOGES, S., RONCAL, C., CARMELIET, P.

“…Strategies to alter angiogenesis have been successfully translated from the bench to bedside. With an estimated number of more than 500 million patients…”
Get full text

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma by Waizenegger, J S, Ben-Batalla, I, Weinhold, N, Meissner, T, Wroblewski, M, Janning, M, Riecken, K, Binder, M, Atanackovic, D, Taipaleenmaeki, H, Schewe, D, Sawall, S, Gensch, V, Cubas-Cordova, M, Seckinger, A, Fiedler, W, Hesse, E, Kröger, N, Fehse, B, Hose, D, Klein, B, Raab, M S, Pantel, K, Bokemeyer, C, Loges, S

“…Multiple myeloma is a mostly incurable malignancy characterized by the expansion of a malignant plasma cell (PC) clone in the human bone marrow (BM). Myeloma…”
Get full text

Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma by Waizenegger, J. S., Ben-Batalla, I., Weinhold, N., Meissner, T., Wroblewski, M., Janning, M., Riecken, K., Binder, M., Atanackovic, D., Taipaleenmaeki, H., Schewe, D., Sawall, S., Gensch, V., Cubas-Cordova, M., Seckinger, A., Fiedler, W., Hesse, E., Kröger, N., Fehse, B., Hose, D., Klein, B., Raab, M. S., Pantel, K., Bokemeyer, C., Loges, S.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo by Alsadeq, A, Strube, S, Krause, S, Carlet, M, Jeremias, I, Vokuhl, C, Loges, S, Aguirre-Ghiso, J A, Trauzold, A, Cario, G, Stanulla, M, Schrappe, M, Schewe, D M

“…P38α/β has been described as a tumor-suppressor controlling cell cycle checkpoints and senescence in epithelial malignancies. However, p38α/β also regulates…”
Get full text

P548: BEMCENTINIB COMBINED WITH LOW‐DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408) by Loges, S., Heuser, M., Chromik, J., Sutamtewagul, G., Kapp‐Schwoerer, S., Crugnola, M., Di Renzo, N., Lemoli, R., Mattei, D., Ben‐Batalla, I., Waizenegger, J., Rieckmann, L.‐M., Janning, M., Imbusch, C. D., Beumer, N., Micklem, D., Gorcea‐Carson, C., Lawson, G., Nautiyal, J., Deharo, S., Fiedler, W., Alvarado‐Valero, Y., Gjertsen, B.

Get full text

Expression of TGF-β receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia by Otten, J, Schmitz, L, Vettorazzi, E, Schultze, A, Marx, A H, Simon, R, Krauter, J, Loges, S, Sauter, G, Bokemeyer, C, Fiedler, W

Get full text

Antiangiogenic treatment with endostatin inhibits progression of AML in vivo by SCHUCH, G, OLIVEIRA-FERRER, L, LOGES, S, LAACK, E, BOKEMEYER, C, HOSSFELD, D. K, FIEDLER, W, ERGUN, S

“…Increased vessel density in the bone marrow of patients with acute myeloid leukemia as well as elevated expression of proangiogenic factors by leukemic cells…”
Get full text

A Major CYP2D6 Autoepitope in Autoimmune Hepatitis Type 2 and Chronic Hepatitis C is a Three-dimensional Structure Homologous to Other Cytochrome P450 Autoantigens by Sugimura, T., Obermayer-Straub, P., Kayser, A., Braun, S., Loges, S., Alex, B., Lüttig, B., Johnson, E.F., Manns, Michael P., Strassburg, Christian P.

“…Liver-kidney microsomal antibodies type 1 (LKM) are a diagnostic marker for autoimmune hepatitis type 2 (AIH-2), however, LKM autoantibodies are also detected…”
Get full text

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM) by Janning, M., Süptitz, J., Albers-Leischner, C., Delpy, P., Tufman, A., Velthaus-Rusik, J.-L., Reck, M., Jung, A., Kauffmann-Guerrero, D., Bonzheim, I., Brändlein, S., Hummel, H.-D., Wiesweg, M., Schildhaus, H.-U., Stratmann, J.A., Sebastian, M., Alt, J., Buth, J., Esposito, I., Berger, J., Tögel, L., Saalfeld, F.C., Wermke, M., Merkelbach-Bruse, S., Hillmer, A.M., Klauschen, F., Bokemeyer, C., Buettner, R., Wolf, J., Loges, S., Simon, Ronald, Sauter, Guido, Volk, Alexander, Neumann, Jens, Klauschen, Frederick, Weichert, Wilko, Kalhori, Naser, Lüthen, Reinhard, Stöhr, Robert, Schubart, Chistoph, Wacker, Heidemarie, Fuchs, Florian, Hartmann, Nils, Graf, Stefanie, Brandts, Christian, Wild, Peter, Demes, Melanie, Reis, Henning, Rohde, Gernot

“…Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer (NSCLC) patients with EGFR mutations and their sensitivity to classical epidermal growth…”
Get full text

991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB) by Kron, A., Scheffler, M., Ihle, M., Michels, S., Süptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R.N., Eisert, A.K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Büttner, R., Wolf, J.

Get full text

1431P The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance by Ziegler, M., Albers-Leischner, C., Salgueiro, L., Khoury, N., Sharapova, Y., Saalfeld, F.C., Wenzel, C., Scharpenseel, H., Schmidt, C., Naveja-Romero, J., Meemboor, S., Hillmer, A., Nogova, L., Wermke, M., Wolf, J., Diederichs, S., Brummer, T., Büttner, R., Janning, M., Loges, S.

Get full text